New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
17:41 EDTFRXForest Labs to present cariprazine results from a Phase 3 trial
Forest Laboratories announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration, FDA, for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar I disorder.
News For FRX From The Last 14 Days
Check below for free stories on FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
05:50 EDTFRXForest Labs reports FDA provided feedback on combination aclidinium, formoterol
Forest Laboratories announced that they have recently received feedback from the FDA regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC, or Chemistry, Manufacturing and Control, and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use